论文部分内容阅读
虽然卵巢癌对手术、放疗和化疗都有效果,但仍难治愈。第16届国际妇产联盟(FIGO)年度报告中1963～1968年治疗的病例,总的五年生存率为27%。美国在过去的20年中五年生存率仅稍有改善。由于同样大范围的肿瘤类型和分期应用的治疗方式有很大差异,故确定理想的治疗方法是困难的。大多数报导都是回顾性的分析,没有考虑任何选择的因素。因此,1970年Minnesota大学妇产科和放射治疗科开始前瞻的试验性研究,应用放射和梅法兰(即左旋溶肉瘤素,Melphalan)作为上皮性卵巢癌术后的辅助治疗。主要目的有三:改善总的生存率,鉴定治疗计划的毒性反应,证实最可能有利于治疗的亚组。
Although ovarian cancer surgery, radiotherapy and chemotherapy have effects, but still difficult to cure. In the FIGO report of the 16th World Health Organization (1963-1968), the overall five-year survival rate was 27%. The five-year survival rate in the United States has improved only slightly over the past two decades. Since the same broad range of tumor types and methods of treatment for staging vary widely, it is difficult to determine the ideal method of treatment. Most reports are retrospective analysis, did not consider any choice factor. Thus, a prospective, pilot study of the Department of Obstetrics and Gynecology and Radiotherapy at the University of Minnesota began in 1970 as a adjuvant postoperative adjuvant treatment of epithelial ovarian cancer with radiofrequency ablation and melphalan (levosarcoma, Melphalan). There are three main goals: to improve the overall survival rate, to identify the toxicity of the treatment plan, and to confirm the subgroup that is most likely to benefit the treatment.